Sunshine Coast University Private Hospital

Birtinya, Queensland QLD 4575

9 studies enrolling now · 15 studies all time

What they study most

Advanced Breast Cancer, Advanced Cancer, Advanced Solid Tumor, Advanced Solid Tumors, Advanced/Metastatic Solid Tumors, HER2-negative Breast Cancer, HR+/HER2- Breast Cancer, Hormone-receptor-positive Breast Cancer, Locally Advanced Unresectable or Metastatic Solid Tumors, Metastatic Breast Cancer, Metastatic HER2-positive Breast Cancer, Non-Small Cell Lung Cancer

Studies at this site

• BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease — Recruiting now
• A Study of BG-C477 in Participants With Advanced Solid Tumors — Recruiting now
• A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors. — Recruiting now
• BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer — Recruiting now
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors — Recruiting now
• A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors — Recruiting now
• ARC101 in Advanced Solid Tumors — Recruiting now
• A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer — Recruiting now
• A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer — Recruiting now
• An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Running, not enrolling
• A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer — Running, not enrolling
• Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) — Running, not enrolling
• Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis — Completed
• ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors — Completed